General form of registration statement for all companies including face-amount certificate companies

Stock-based Compensation (Details Narrative)

v3.19.3.a.u2
Stock-based Compensation (Details Narrative) - USD ($)
3 Months Ended 9 Months Ended 12 Months Ended
Jun. 20, 2019
Sep. 30, 2019
Sep. 30, 2018
Sep. 30, 2019
Sep. 30, 2018
Dec. 31, 2018
Dec. 31, 2017
Stock option contractual term           9 years 10 months 25 days  
Stock option exercise price           $ 2.92
Number of stock option granted           384,400  
Number of options outstanding   1,293,630 334,400 1,293,630 334,400 384,400
Number of option purchase during period for vested       187,746      
Stock-based compensation expense   $ 269,129 $ 50,528 $ 394,164 $ 50,528 $ 74,063  
Employees [Member]              
Stock option contractual term 5 years            
Stock option exercise price $ 2.40            
Employees [Member] | Tranche One [Member] | Three Year Service Vesting [Member]              
Number of stock option granted 456,000            
Employees [Member] | Tranche Two [Member] | Phase 2a trial for PCS-499 Complete [Member]              
Number of stock option granted 90,646            
Employees [Member] | Tranche Two [Member] | Up-List From The OCTQB [Member]              
Number of stock option granted 271,938            
Employees [Member] | Tranche Two [Member] | In-license a new or additional drug [Member]              
Number of stock option granted 90,646            
Employees and Non-Employees [Member]              
Number of stock option granted         334,400